Author: Bicara Therapeutics Inc.

Posted Date:

February 24, 2026

Bicara Therapeutics Announces Proposed Public Offering of Common Stock

Bicara Therapeutics Inc.

February 24, 2026
Bicara Therapeutics to Participate in Upcoming Investor Conferences

Bicara Therapeutics Inc.

February 23, 2026
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen

Bicara Therapeutics Inc.

February 19, 2026
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Inc.

February 8, 2026